BMY - BRISTOL MYERS SQUIBB CO
59.12
-0.380 -0.643%
Share volume: 11,676,181
Last Updated: Tue 04 Feb 2025 10:00:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.24%
PREVIOUS CLOSE
CHG
CHG%
$59.50
-0.83
-0.01%
Fundamental analysis
39%
Profitability
5%
Dept financing
49%
Liquidity
70%
Performance
64%
Performance
5 Days
0.29%
1 Month
4.30%
3 Months
5.67%
6 Months
24.23%
1 Year
23.22%
2 Year
-20.68%
Key data
Stock price
$59.12
DAY RANGE
$58.73 - $59.85
52 WEEK RANGE
$39.35 - $61.10
52 WEEK CHANGE
$21.55
DIVIDEND
$0.60
EX-DIVIDEND DATE
07/05/2024
NEXT EARNINGS DATE
N/A
Company detail
CEO: Giovanni Caforio
Region: US
Website: bms.com
Employees: 34,300
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: bms.com
Employees: 34,300
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma.
Recent news